 |
 |
|
Home |
Current Issue |
Past Issues |
In the Clinic |
ACP Journal Club |
CME |
Collections |
Audio/Video |
Mobile |
Subscribe |
Tools |
Help |
ACP Online
|
1 May 1997 | Volume 126 Issue 9 | Pages 673-681
Background: Thrombocytopenia is frequently encountered in patients with cancer. It is associated with an increased risk for clinically important bleeding episodes, which increases the demand for platelet transfusion.
Objective: To assess hematopoietic response to and clinical tolerance of recombinant human thrombopoietin, a recently cloned novel cytokine.
Design: Phase I and II clinical cohort study.
Setting: The University of Texas M.D. Anderson Cancer Center, Houston, Texas.
Patients: 12 patients with sarcoma who had high risk for severe chemotherapy-induced thrombocytopenia.
Intervention: A single intravenous dose of thrombopoietin (0.3 to 2.4 µg/kg of body weight) 3 weeks before chemotherapy.
Measurements: Peripheral blood and bone marrow evaluation before and after thrombopoietin administration.
Results: A single dose of thrombopoietin was associated with an increase in platelet counts (mean increase from baseline, 61% to 213%; P = 0.002) in a dose-related manner. This increase began by day 4 in most patients and peaked on a median of day 12. This sustained response was associated with a prolonged serum thrombopoietin half life (20 to 30 hours). The platelets appeared morphologically normal and showed normal aggregation in response to various agonists. Platelet response was accompanied by a dose-related increase in bone marrow megakaryocytes (as much as 4-fold); the expansion of the bone marrow progenitors of myeloid, erythroid, multipotential, and megakaryocytic lineages; and the marked mobilization of progenitors (maximum, 5.7-fold to 10-fold) of multiple cell lineages in the peripheral blood. Treatment was well tolerated, and no serious adverse events occurred.
Conclusions: Thrombopoietin, administered as a single dose, is a potent stimulus for prolonged platelet production in humans. It merits further evaluation for the prevention and treatment of thrombocytopenia.
Author and Article Information
From The University of Texas M.D. Anderson Cancer Center, Houston, Texas; SyStemix, Inc., San Francisco, California; Genentech, Inc., South San Francisco, California; and Indiana University School of Medicine, Indianapolis, Indiana.
ARTICLE
Stimulation of Megakaryocyte and Platelet Production by a Single Dose of Recombinant Human Thrombopoietin in Patients with Cancer
Acknowledgments: The authors thank Duane Bloedow, PhD, and Tauri Senn for their help in pharmacokinetics analysis; Yang Huh, MD, for immunophenotypic analysis; Karin Luens for ploidy analysis; Debbie Sayre and Nancy Hague for technical assistance; and Zenaida Silva for manuscript preparation.
Grant Support: In part by R01 HL56416, R01 HL54037, and P01 HL53586 from the National Heart, Lung, and Blood Institute and by a research grant from Genentech, Inc. (South San Francisco, California).
Requests for Reprints: Saroj Vadhan-Raj, MD, Department of Bioimmunotherapy, Box 002, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030.
Current Author Addresses: Drs. Vadhan-Raj and Reddy and Ms. Johnston: Department of Bioimmunotherapy, Box 002, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030.
Related articles in Annals:
This article has been cited by other articles:
|
|
 |
|
  J. E. Baker, J. Su, A. Hsu, Y. Shi, M. Zhao, J. L. Strande, X. Fu, H. Xu, A. Eis, R. Komorowski, et al. Human thrombopoietin reduces myocardial infarct size, apoptosis, and stunning following ischaemia/reperfusion in rats Cardiovasc Res, January 1, 2008; 77(1): 44 - 53. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. J. Kuter New thrombopoietic growth factors Blood, June 1, 2007; 109(11): 4607 - 4616. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Frederickson, M. W. Renshaw, B. Lin, L. M. Smith, P. Calveley, J. P. Springhorn, K. Johnson, Y. Wang, X. Su, Y. Shen, et al. A rationally designed agonist antibody fragment that functionally mimics thrombopoietin PNAS, September 26, 2006; 103(39): 14307 - 14312. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. L. Angiolillo, V. Davenport, M. A. Bonilla, C. van de Ven, J. Ayello, O. Militano, L. L. Miller, M. Krailo, G. Reaman, and M. S. Cairo A Phase I Clinical, Pharmacologic, and Biologic Study of Thrombopoietin and Granulocyte Colony-Stimulating Factor in Children Receiving Ifosfamide, Carboplatin, and Etoposide Chemotherapy for Recurrent or Refractory Solid Tumors: A Children's Oncology Group Experience Clin. Cancer Res., April 1, 2005; 11(7): 2644 - 2650. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Kurzrock Thrombopoietic Factors in Chronic Bone Marrow Failure States: The Platelet Problem Revisited Clin. Cancer Res., February 15, 2005; 11(4): 1361 - 1367. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Vadhan-Raj, S. Patel, C. Bueso-Ramos, J. Folloder, N. Papadopolous, A. Burgess, L. D. Broemeling, H. E. Broxmeyer, and R. S. Benjamin Importance of Predosing of Recombinant Human Thrombopoietin to Reduce Chemotherapy-Induced Early Thrombocytopenia J. Clin. Oncol., August 15, 2003; 21(16): 3158 - 3167. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. H. Gunawardana, R. L. Basser, I. D. Davis, J. Cebon, P. Mitchell, C. Underhill, T. J. Kilpatrick, K. Reardon, M. D. Green, P. Bardy, et al. A Phase I Study of Recombinant Human Leukemia Inhibitory Factor in Patients with Advanced Cancer Clin. Cancer Res., June 1, 2003; 9(6): 2056 - 2065. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. J. Kuter and C. G. Begley Recombinant human thrombopoietin: basic biology and evaluation of clinical studies Blood, November 15, 2002; 100(10): 3457 - 3469. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. C. Haznedaroglu, H. Goker, M. Turgut, Y. Buyukasik, and M. Benekli Thrombopoietin as a Drug: Biologic Expectations, Clinical Realities, and Future Directions Clinical and Applied Thrombosis/Hemostasis, July 1, 2002; 8(3): 193 - 212. [Abstract] [PDF]
|
|
|
|
|
|
K. Kaushansky, N. Fox, N. L. Lin, and W. C. Liles Lineage-specific growth factors can compensate for stem and progenitor cell deficiencies at the postprogenitor cell level: an analysis of doubly TPO- and G-CSF receptor-deficient mice Blood, May 15, 2002; 99(10): 3573 - 3578. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. L. Basser, E. O'Flaherty, M. Green, M. Edmonds, J. Nichol, D. M. Menchaca, B. Cohen, and C. G. Begley Development of pancytopenia with neutralizing antibodies to thrombopoietin after multicycle chemotherapy supported by megakaryocyte growth and development factor Blood, April 1, 2002; 99(7): 2599 - 2602. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Li, C. Yang, Y. Xia, A. Bertino, J. Glaspy, M. Roberts, and D. J. Kuter Thrombocytopenia caused by the development of antibodies to thrombopoietin Blood, December 1, 2001; 98(12): 3241 - 3248. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Kaser, G. Brandacher, W. Steurer, S. Kaser, F. A. Offner, H. Zoller, I. Theurl, W. Widder, C. Molnar, O. Ludwiczek, et al. Interleukin-6 stimulates thrombopoiesis through thrombopoietin: role in inflammatory thrombocytosis Blood, November 1, 2001; 98(9): 2720 - 2725. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. D. Demetri Targeted Approaches for the Treatment of Thrombocytopenia Oncologist, October 1, 2001; 6(2008): 15 - 23. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. C. Case, M. L. Hauck, R. L. Yeager, A. H. Simkins, M. de Serres, V. D. Schmith, J. E. Dillberger, and R. L. Page The Pharmacokinetics and Pharmacodynamics of GW395058, a Peptide Agonist of the Thrombopoietin Receptor, in the Dog, a Large-Animal Model of Chemotherapy-Induced Thrombocytopenia Stem Cells, September 1, 2000; 18(5): 360 - 365. [Abstract] [Full Text]
|
|
|
|
|
|
R. L. Basser, C. Underhill, I. Davis, M. D. Green, J. Cebon, J. Zalcberg, J. MacMillan, B. Cohen, J. Marty, R. M. Fox, et al. Enhancement of Platelet Recovery After Myelosuppressive Chemotherapy by Recombinant Human Megakaryocyte Growth and Development Factor in Patients With Advanced Cancer J. Clin. Oncol., August 15, 2000; 18(15): 2852 - 2861. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. A. Harker, L. K. Roskos, U. M. Marzec, R. A. Carter, J. K. Cherry, B. Sundell, E. N. Cheung, D. Terry, and W. Sheridan Effects of megakaryocyte growth and development factor on platelet production, platelet life span, and platelet function in healthy human volunteers Blood, April 15, 2000; 95(8): 2514 - 2522. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Vadhan-Raj, C. F. Verschraegen, C. Bueso-Ramos, H. E. Broxmeyer, A. P. Kudelka, R. S. Freedman, C. L. Edwards, D. Gershenson, D. Jones, M. Ashby, et al. Recombinant Human Thrombopoietin Attenuates Carboplatin-Induced Severe Thrombocytopenia and the Need for Platelet Transfusions in Patients with Gynecologic Cancer Ann Intern Med, March 7, 2000; 132(5): 364 - 368. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Peck-Radosavljevic, M. Wichlas, J. Zacherl, G. Stiegler, P. Stohlawetz, M. Fuchsjager, A. Kreil, S. Metz-Schimmerl, S. Panzer, R. Steininger, et al. Thrombopoietin induces rapid resolution of thrombocytopenia after orthotopic liver transplantation through increased platelet production Blood, February 1, 2000; 95(3): 795 - 801. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. De Serres, B. Ellis, J. E. Dillberger, S. K. Rudolph, J. T. Hutchins, C. M. Boytos, D. L. Weigl, and R. B. DePrince Immunogenicity of Thrombopoietin Mimetic Peptide GW395058 in BALB/c Mice and New Zealand White Rabbits: Evaluation of the Potential for Thrombopoietin Neutralizing Antibody Production in Man Stem Cells, July 1, 1999; 17(4): 203 - 209. [Abstract] [Full Text]
|
|
|
|
|
|
G. Somlo, I. Sniecinski, A. ter Veer, J. Longmate, G. Knutson, S. Vuk-Pavlovic, R. Bhatia, W. Chow, L. Leong, R. Morgan, et al. Recombinant Human Thrombopoietin in Combination With Granulocyte Colony-Stimulating Factor Enhances Mobilization of Peripheral Blood Progenitor Cells, Increases Peripheral Blood Platelet Concentration, and Accelerates Hematopoietic Recovery Following High-Dose Chemotherapy Blood, May 1, 1999; 93(9): 2798 - 2806. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Kaushansky Thrombopoietin N. Engl. J. Med., September 10, 1998; 339(11): 746 - 754. [Full Text] [PDF]
|
|
|
|
|
|
M. Murone, D. A. Carpenter, and F. J. de Sauvage Hematopoietic Deficiencies in c-mpl and TPO Knockout Mice Stem Cells, January 1, 1998; 16(1): 1 - 6. [Abstract] [Full Text]
|
|
|
|
|
|
A. Ritchie, A. Gotoh, J. Gaddy, S. E. Braun, and H. E. Broxmeyer Thrombopoietin Upregulates the Promoter Conformation of p53 in a Proliferation-Independent Manner Coincident With a Decreased Expression of Bax: Potential Mechanisms for Survival Enhancing Effects Blood, December 1, 1997; 90(11): 4394 - 4402. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Abraham and R. L. Basser Megakaryocyte Growth and Development Factor: A Review of Early Clinical Studies Oncologist, October 1, 1997; 2(5): 311 - 318. [Abstract] [Full Text] [PDF]
|
|
Article
